Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note

Neurology. 2007 Mar 20;68(12):955-6. doi: 10.1212/01.wnl.0000259430.48835.b5.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects
  • Brain Neoplasms / drug therapy*
  • DNA, Viral / blood
  • DNA, Viral / drug effects
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Glioblastoma / drug therapy*
  • Hepatitis B / chemically induced*
  • Hepatitis B / immunology
  • Hepatitis B / physiopathology
  • Humans
  • Immunocompromised Host / immunology
  • Immunosuppression Therapy / adverse effects*
  • Lamivudine / therapeutic use
  • Liver / drug effects
  • Liver / physiopathology
  • Liver / virology
  • Male
  • Middle Aged
  • Patient Selection
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Risk Factors
  • Spinal Neoplasms / secondary*
  • Spinal Neoplasms / therapy
  • Temozolomide
  • Treatment Outcome
  • Viral Load
  • Virus Activation / drug effects
  • Virus Activation / genetics

Substances

  • Antineoplastic Agents, Alkylating
  • DNA, Viral
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Dacarbazine
  • Temozolomide